Unintended immunomodulation: part I. Effects of common clinical conditions on cytokine biosynthesis.
Cytokines are low molecular weight proteins that act in an autocrine, paracrine and endocrine fashion to regulate and integrate immune effector cell function. Cytokine production is tightly controlled by a complex network of co-stimulatory and feedback loops. The systemic concentrations of some cytokines, most notably tumor necrosis factor and various interleukins, correlate with the extent of inflammation, and the severity of critical illness and patient outcome. Thus, cytokine expression is often monitored and/or manipulated as a therapeutic target in studies of sepsis and other inflammatory conditions. Unfortunately, some therapies designed to modify cytokine response have failed to improve outcomes in sepsis, and some of these therapies have actually been harmful. Several common clinical conditions, as well as, therapeutic interventions significantly influence cytokine expression. Furthermore, the magnitude and extent of these effects may be greater than those produced by immunomodulating therapies. In contrast, other conditions may not produce clinically significant changes in cytokine expression, and must simply be considered when interpreting studies designed to determine the effects of immunomodulation. Some conditions may even result in changes in the inflammatory response and may thus add to the inflammatory burden of a critically ill patient. This review provides intensivists and other clinicians with an overview of the effects of altered physiologic conditions on cytokine expression. This information is important so that studies measuring cytokines can be correctly interpreted and clinical circumstances in which cytokine manipulation is undesirable can perhaps be avoided.
Alkharfy
K M
KM
Department of Pharmaceutical Sciences, School of Pharmacy, the University of Pittsburgh, Pennsylvania 15261, USA.
Kellum
J A
JA
Matzke
G R
GR
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000740:Anemia / Q000276:immunology; D016638:Critical Illness; D016207:Cytokines / Q000096:biosynthesis* / Q000097:blood; D006470:Hemorrhage / Q000276:immunology; D006801:Humans; D006943:Hyperglycemia / Q000276:immunology; D007003:Hypoglycemia / Q000276:immunology; D007022:Hypotension / Q000276:immunology; D007249:Inflammation / Q000276:immunology; D007511:Ischemia / Q000276:immunology; D009752:Nutritional Status; D015427:Reperfusion Injury / Q000276:immunology
D000276:Adjuvants, Immunologic; D016207:Cytokines